Lightnews — Scholar-powered news

Reposted by Dr. Herbert Loong

Prof Tom John @drtomjohn.bsky.social · Sep 6

Looking forward to playing with @drsanjaypopat.bsky.social - a lot of fun rehearsing covers and @mayhemtomi tracks. Check us out tonight @iaslc.bsky.social #wclc2025

1 3 8

Dr. Herbert Loong @herbloongmd.bsky.social · Sep 6

The @ascocancer.bsky.social
#InternationalAffairsCommittee #2025-26. An absolute delight and pleasure working with these highly engaged professionals from across the world 🌎 and across oncology disciplines. #BestASCOCommittee

1 1 2

Dr. Herbert Loong @herbloongmd.bsky.social · Aug 31

It's always a pleasure meeting #colleagues on home turf in #hongkong 🇭🇰 after a long day of clinic. #LCSM @cuhkmedicine.bsky.social

1

Dr. Herbert Loong @herbloongmd.bsky.social · Aug 31

Whirlwind 2 days in #Manila at #PSMO
@astra-zeneca.bsky.social 🫁 #lungcancer #preceptorship w/ colleagues & experts including @KSamalaMD #ArthurLui 🇵🇭 together w/ #QuincyChu of @AlbertaUni 🇨🇦. Covered broad topics: #targetedtherapies, #IO, #EGFR and #SCLC. #LCSM
@cuhkmedicine.bsky.social @APCLC_2023

Dr. Herbert Loong @herbloongmd.bsky.social · Aug 16

Enhancing cost-effectiveness considerations in the adoption of new drugs in Hong Kong www.hkmj.org/abstracts/v3...

Enhancing cost-effectiveness considerations in the adoption of new drugs in Hong Kong | HKMJ

Hong Kong Med J 2025 Aug;31(4):312–5 | Epub 23 Jul 2025 https://doi.org/10.12809/hkmj2412259 © Hong Kong Academy of Medicine.

www.hkmj.org

1

Dr. Herbert Loong @herbloongmd.bsky.social · Jul 29

#ImprovingAccess to #effectivetherapies is mandate all physicians should uphold. How to incorporate these whilst balancing societal costs require guidelines & discussions. Our position paper on "Enhancing cost-effectiveness considerations in adoption of new drugs in HK" www.hkmj.org/earlyrelease...

Enhancing cost-effectiveness considerations in the adoption of new drugs in Hong Kong | HKMJ

Hong Kong Med J 2025;31:Epub 23 Jul 2025 https://doi.org/10.12809/hkmj2412259 © Hong Kong Academy of Medicine.

www.hkmj.org

Reposted by Dr. Herbert Loong

OncoDaily @oncodaily.bsky.social · Jul 26

The Strong International Camaraderie Between Past and Present Fellows of the PMH Fellowship - Herbert Loong
@herbloongmd.bsky.social
@pmresearch-uhn.bsky.social

oncodaily.com/blog/herbert...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #PMHFellowship

Herbert Loong: The Strong International Camaraderie Between Past and Present Fellows of the PMH Fellowship - OncoDaily

Herbert Loong: The Strong International Camaraderie Between Past and Present Fellows of the PMH Fellowship / Abdul Razak, Albiruni Ryan, cancer, Herbert

oncodaily.com

1 6

Dr. Herbert Loong @herbloongmd.bsky.social · Jul 24

🇭🇰🚝✈️🇨🇦🚗🏥=🤩 Looking forward to #returning to #Toronto & my alma mater @uhnresearch.ca #PrincessMargaretCancerCentre for a short visit this weekend! Very honoured and privileged to be able to give #GrandRounds 🎙️

Best way to fight jetlag! See you soon!👋

#LCSM #Sarcoma #CUHKSarcoma #precisiononcology

2 2

Dr. Herbert Loong @herbloongmd.bsky.social · Jul 15

Putting final touches together to my talk😀. Looking forward to welcoming you all to #hongkong 🇭🇰 for #ESMOTATAsia25! Don't be shy - come by and say hi!

#drugdevelopment @cuhkmedicine.bsky.social @apoddc @APCLC_2023

2

Dr. Herbert Loong @herbloongmd.bsky.social · Jul 14

#PublicEducation on #sarcomas can be fun! 😃 #facialkexpressions #CannotHideHit #HappyMonday #CUHKSarcoma

youtu.be/XesQlcQPMOY?...

Reposted by Dr. Herbert Loong

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Jul 11

One week until the inaugural #ESMOTATAsia25 🤩
I'm looking forward to joining global drug development experts in🍜🇭🇰
+ sharing insights on dose optimisation of novel combinations
🗓️ Saturday 19 July 2pm.
@myesmo.bsky.social @herbloongmd.bsky.social @anmwongnz.bsky.social

2 7

Dr. Herbert Loong @herbloongmd.bsky.social · Jun 26

Incorporating high-risk individuals beyond smoking history into lung cancer screening in Hong Kong: a cost-effectiveness study - JTO Clinical and Research Reports www.jtocrr.org/article/S266...

Incorporating high-risk individuals beyond smoking history into lung cancer screening in Hong Kong: a cost-effectiveness study

Lung cancer (LC) accounts for 26.4% of all cancer deaths in Hong Kong (HK). Lung cancer screening (LCS) with low-dose computed tomography (LDCT) can reduce LC mortality. The cost-effectiveness of LDCT...

www.jtocrr.org

1

Dr. Herbert Loong @herbloongmd.bsky.social · Jun 24

Thanks @liferaftgroup.bsky.social for opportunity to share some key #GIST updates from #ASCO25 w/ wider patients' community 🌎 through this webinar last week.

@srothschild @cuhkmedicine.bsky.social @GISTNetwork @ctosociety #DrugDevelopment #sarcomas #CUHKSarcoma

youtu.be/uoZULT8YlPU?...

Updates from ASCO 2025 Annual Meeting

YouTube video by The Life Raft Group

youtu.be

1 3

Dr. Herbert Loong @herbloongmd.bsky.social · Jun 19

Come join us in a couple of hours as we discuss several #abstracts related to #GISTs presented at #ASCO25!

Registration is free! Register here: us02web.zoom.us/webinar/regi...

@liferaftgroup.bsky.social @ctosociety #sarcoma @cuhkmedicine.bsky.social #CUHKSarcoma #PublicEducation

Dr. Herbert Loong @herbloongmd.bsky.social · Jun 10

After serving on #MembershipCommittee, I look forward to returning to #CommunicationsCommittee
@iaslc.bsky.social w/ #LCSM colleagues from around the World 🌐 to create #effective, #efficient & #robust channels of communications between our society & community. @CUHKMedicine @apoddc @APCLC_2023

1

Reposted by Dr. Herbert Loong

OncLive @onclive.bsky.social · Jun 1

Sevabertinib Induces Durable Response in Advanced HER2-Mutant NSCLC #lungcancer #NSCLC #ASCO25 @herbloongmd.bsky.social @ascocancer.bsky.social
www.onclive.com/view/sevaber...

Sevabertinib Induces Durable Response in Advanced HER2-Mutant NSCLC

Treatment with the oral TKI showed promising responses among 2 subgroups of patients with advanced, HER2-mutant non–small cell lung cancer.

www.onclive.com

1 1

Dr. Herbert Loong @herbloongmd.bsky.social · Jun 1

#Honoured and #humbled to have been awarded #FASCO at @ascocancer.bsky.social #ASCO25. My thanks to my friends and colleagues for your overwhelming support along the way 😊

#sarcoma #LCSM #InternationalAffairsCommittee #drugdevelopment #precisiononcology

1 2

Dr. Herbert Loong @herbloongmd.bsky.social · May 30

Thanks @stern-sydney.bsky.social! I am humbled and credits should go to you for all that you are doing for the #TGCT community and beyond! Looking forward to seeing your presentation! 😀 #CTOSTweeTOS #Sarcoma

1 1

Dr. Herbert Loong @herbloongmd.bsky.social · May 29

T-13hrs 59mins before landing in #Chicago for @ascocancer.bsky.social #ASCO25! ✈️ full of oncology colleagues from 🇭🇰🇵🇭 and from 🇦🇺🦘🐨😀.

What’s the combined H-index of this flight? 🧐

Looking fwd to days of #scientificexchanges and #interactivediscussions. Safe travels everyone! See you at McCormick!

3

Dr. Herbert Loong @herbloongmd.bsky.social · May 26

As @ascocancer.bsky.social #ASCO25 is round the corner, so is the end of my #chair of #InternationalAffairsCommittee.

Tks all my colleagues & friends from around the World 🌍 for continuous support.

Time to pass torch 🔥 to Dr. Monica Malik who will continue to push our global agenda forward!

1 4

Dr. Herbert Loong @herbloongmd.bsky.social · May 7

Come join us in #hongkong 🇭🇰 🍜🥟🥡 for the #inaugural @myesmo.bsky.social #ESMOTATAsia25 on July 18-20, 2025! We have assembled a #stellar group of #international #faculties and #experts in #drugdevelopment to help move the field forward. Register today!

2 4

Reposted by Dr. Herbert Loong

OncLive @onclive.bsky.social · Apr 29

Thanks to Dr Herbert Loong, of The Chinese University of Hong Kong, for speaking with us during #AACR25 about the efficacy of D3S-001 in KRAS G12C inhibitor–resistant NSCLC! See our site for more meeting insights! @theaacr.bsky.social #lcsm #oncology
www.onclive.com/conference/a...

1 1

Dr. Herbert Loong @herbloongmd.bsky.social · Apr 30

Thanks my #coinvestigators for opportunity to present data of #D3S_001, a novel #KRASG12C inhibitor in #G12Ci pre-treated #NSCLC at @theaacr.bsky.social #AACR25. Strong & rapid #targetengagement confer superior #efficacy c.f. 1st generation G12Ci.

✔️ORR 30%; DCR 80% in KRASG12Ci pre-treated popn.

2

Dr. Herbert Loong @herbloongmd.bsky.social · Apr 28

Better late than never! 🤣 Arrived in #Chicago for @theaacr.bsky.social #AACR25 after 14 hours flight ✈️ and looking forward to the #ClinicalTrials #Minisymposium tomorrow.

1 3

Dr. Herbert Loong @herbloongmd.bsky.social · Apr 28

Wonderful opportunity to #share & #discuss emerging role of #TCellEngagers #BiTEs in Mx of #SCLC 🫁 w/ our Malaysian 🇲🇾 colleagues during #LCS2025.

Small group discussions (esp. over a meal! 😋) are always very interactive for experience sharing.

#LCSM @APCLC_2023 @apoddc @cuhkmedicine.bsky.social